H.C. Wainwright analyst Swayampakula Ramakanth upgraded Alaunos Therapeutics (TCRT – Research Report) to a Buy today and set a price target of $1.50. The company’s shares closed last Friday at $0.57.
According to TipRanks, Ramakanth is an analyst with an average return of -17.1% and a 28.06% success rate. Ramakanth covers the Healthcare sector, focusing on stocks such as Rewalk Robotics, Ocugen, and Asensus Surgical.
Alaunos Therapeutics has an analyst consensus of Moderate Buy, with a price target consensus of $2.25.
See today’s best-performing stocks on TipRanks >>
The company has a one-year high of $4.01 and a one-year low of $0.45. Currently, Alaunos Therapeutics has an average volume of 617.3K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
ZIOPHARM Oncology, Inc. is a biopharmaceutical company, which engages in the development, acquisition, and commercialization of a diverse portfolio of cancer therapies. It focuses on developing products in immuno-oncology that employ novel gene expression, control, and cell technologies for the treatment of cancer. The company was founded on September 9, 2003 and is headquartered in Boston, MA.
Read More on TCRT:
- Alaunos Therapeutics Reports First Quarter 2023 Financial Results
- TCRT Upcoming Earnings Report: What to Expect?
- Alaunos Therapeutics to Report First Quarter 2023 Financial Results on May 10, 2023
- Alaunos Therapeutics Announces Poster Presentation at the American Society of Clinical Oncology (ASCO) 2023 Annual Meeting
- Precigen amends exclusive license agreement with Alaunos Therapeutics
